GET DAILY SIGNALSWhy Is Globus Medical (GMED) Stock Down -7.96% Today?
Key Takeaways
- Shares fell roughly 7.96% to about $74.96, down from the prior session's close of $81.44, extending the stock's post-earnings slide.
- Primary catalyst: Third-quarter revenue missed Wall Street expectations, and management cut its full-year 2026 revenue guidance.
- Secondary drivers: Slower U.S. Spine growth, a sharp decline in Nevro revenue, and weakness in international sales.
- Analyst reaction: A reported downgrade added to selling pressure following the earnings release.
- Broader context: The move occurred amid wider softness in orthopedic and medical device names.
- What's next: Traders are watching whether cost discipline can offset slowing top-line growth heading into 2027.
- For more detail on valuation and expectations, explore Price Targets, Earnings, and Forecast pages for this ticker.
- Interested in automated strategies? Discover today's strongest performers in the Trending AI Robots section.
Opening Summary
GMED, the stock of Globus Medical, Inc., a musculoskeletal technology company focused on spine implants, robotic surgery, and enabling technologies, fell sharply on Thursday, tumbling about 7.96% to roughly $74.96. The decline, which came after the shares closed the prior session at $81.44, marked the second straight day of heavy selling as investors digested the company's third-quarter results and a lowered full-year sales outlook. The immediate trigger cited by markets was a revenue miss and a cut to 2026 revenue guidance, which overshadowed an earnings-per-share beat.
Earnings Results: Revenue Miss and Guidance Cut
The earnings-driven move centered on a top-line shortfall. Globus Medical reported third-quarter revenue of $763.7 million, down 0.7% from a year earlier and below the roughly $792 million analysts had expected. While non-GAAP earnings per share of $1.23 edged past the $1.20 consensus, the profit beat was not enough to reassure investors focused on slowing growth.
More consequential was the company's decision to lower full-year 2026 revenue guidance to $3.09 billion, down from a prior range of $3.18 billion to $3.22 billion. That cut implied growth of about 5.1%, a meaningful deceleration from earlier expectations, even as management reaffirmed its non-GAAP EPS outlook of $4.95 to $5.05. The combination of intact profitability and visibly stalling sales framed the negative market reaction.
U.S. Spine Slowdown and Nevro Drag
Beneath the headline numbers, the deceleration was broad. Growth in the core U.S. Spine business slowed to roughly 2%, down sharply from 7.3% in the prior quarter, as management cited delayed product launches, lingering production issues, and weaker-than-expected contributions from competitive recruiting. Revenue from the Nevro neuromodulation segment fell 25.7% year over year as a recovery in trial volumes slipped into 2027, while international sales declined 5.7% on reported weakness in Japan and integration disruption.
There were bright spots, including a 24% rebound in Enabling Technologies revenue, a 19% increase in trauma sales, and record free cash flow of about $225 million. However, these positives were insufficient to counter the narrative of a growth story that has lost momentum.
Analyst Reaction and Sector Pressure
The selloff was reinforced by analyst action, with a reported downgrade adding to the post-earnings pressure on GMED. The shares had surged roughly 9% ahead of the report, so part of the decline reflected a giveback of that pre-earnings run-up. Sector sympathy also played a role, as several orthopedic and medical device peers traded lower amid broader caution in healthcare names, compounding the company-specific selling.
Market Context and Trading Activity
Trading volume was elevated well above average, reflecting heavy participation as investors repositioned following the results. The decline diverged from the broader market's tone and was driven primarily by company-specific fundamentals rather than a broad risk-off move. Technically, the stock broke below its recent support zone, unwinding much of the sharp rebound that had carried it back toward its 200-day moving average in the weeks before earnings. The move underscored how quickly the stock's earlier momentum reversed once guidance disappointed.
What Comes Next for GMED
Looking ahead, investors will focus on whether management's cost discipline can preserve profitability even as revenue growth decelerates. Key watch items include the timing of new spine product launches, the stabilization of the Nevro business, and the planned 2027 commercial launch of the HFX Elite neuromodulation device. Risks include further delays in product introductions, persistent competitive recruiting challenges, and softer international demand. The reaffirmed EPS guidance suggests the company expects margins and spending restraint to bridge the gap, but the path back to sustained top-line acceleration remains the central uncertainty for GMED.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots, chosen from hundreds of strategies that collectively monitor thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy, timeframe, performance metrics, and the symbols they trade. Explore the page to see which automated strategies are adapting to today's market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
GMED in upward trend: price rose above 50-day moving average on October 20, 2026
GMED moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for GMED crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 203 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
The Aroon Indicator entered an Uptrend today. In 112 of 213 cases where GMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 53%.
Bearish Trend Analysis
The 10-day RSI Indicator for GMED moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 23 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 62 cases where GMED's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GMED as a result. In 48 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.293) is normal, around the industry mean (4.115). P/E Ratio (20.514) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What Is a Stop-Loss Order?
Are Certificates of Deposit a Secure Avenue for Your Savings?
What Are the Economic Significance of "Green Shoots"?
What exactly does a brokerage account entail, including its definition and purpose?
What is the definition of a fiduciary, and could you provide some examples to illustrate this concept?
General Information
a manufacturer of spinal implants
Industry MedicalNursingServices
Advertisement